Breaking News

Financial Report: Quintiles

May 1, 2014

Product Development revenues up 9% in the quarter

Quintiles

1Q Revenues: $1.3 billion (+6%)

1Q Earnings: $90.2 million  (+87%)

Comments: Product Development revenues grew 9% to $770.8 million, with growth in core clinical services in North America, clinical trial support services, and increases in global labs, and the Novella acquisition in 2013. Integrated Healthcare Service revenues were up 8% to $234.5 million, primarily due to increases in Japan and North America, as well as growth in real-world and late phase research services. Net new business wins were $1.27 billion in the quarter, representing a book-to-bill ratio of 1.27, contributing to an ending backlog of $10.1 billion at March 31st.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks